ArticleThe oncologist2025

Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma.

Annette Arndt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.